Literature DB >> 24781030

Regulation of Rad51 promoter.

Christopher M Hine1, Hongjie Li1, Li Xie1, Zhiyong Mao1, Andrei Seluanov1, Vera Gorbunova1.   

Abstract

The DNA double-strand break repair and homologous recombination protein Rad51 is overexpressed in the majority of human cancers. This correlates with therapy resistance and decreased patient survival. We previously showed that constructs containing Rad51 promoter fused to a reporter gene are, on average, 850-fold more active in cancer cells than in normal cells. It is not well understood what factors and sequences regulate the Rad51 promoter and cause its high activity in cancerous cells. Here we characterized regulatory regions and examined genetic requirements for oncogenic stimulation of the Rad51 promoter. We identified specific regions responsible for up- and downregulation of the Rad51 promoter in cancerous cells. Furthermore, we show that Rad51 expression is positively regulated by EGR1 transcription factor. We then modeled the malignant transformation process by expressing a set of oncoproteins in normal human fibroblasts. Expression of different combinations of SV40 large T antigen, oncogenic Ras and SV40 small T antigen resulted in step-wise increase in Rad51 promoter activity, with all the 3 oncoproteins together leading to a 47-fold increase in expression. Cumulatively, these results suggest that Rad51 promoter is regulated by multiple factors, and that its expression is gradually activated as cells progress toward malignancy.

Entities:  

Keywords:  DNA repair; EGR1; Rad51 promoter; cancer; p53; therapy resistance

Mesh:

Substances:

Year:  2014        PMID: 24781030      PMCID: PMC4111695          DOI: 10.4161/cc.29016

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  43 in total

1.  Cell cycle-related transformation of the E2F4-p130 repressor complex.

Authors:  Boris Popov; Long-Sheng Chang; Vladimir Serikov
Journal:  Biochem Biophys Res Commun       Date:  2005-10-28       Impact factor: 3.575

Review 2.  Cancer-specific gene therapy.

Authors:  Hui-Wen Lo; Chi-Ping Day; Mien-Chie Hung
Journal:  Adv Genet       Date:  2005       Impact factor: 1.944

3.  Characterization of the human Rad51 genomic locus and examination of tumors with 15q14-15 loss of heterozygosity (LOH).

Authors:  C Schmutte; G Tombline; K Rhiem; M M Sadoff; R Schmutzler; A von Deimling; R Fishel
Journal:  Cancer Res       Date:  1999-09-15       Impact factor: 12.701

4.  Creation of human tumour cells with defined genetic elements.

Authors:  W C Hahn; C M Counter; A S Lundberg; R L Beijersbergen; M W Brooks; R A Weinberg
Journal:  Nature       Date:  1999-07-29       Impact factor: 49.962

5.  Cell cycle checkpoints, DNA damage/repair, and lung cancer risk.

Authors:  Xifeng Wu; Jack A Roth; Hua Zhao; Sherry Luo; Yun-Ling Zheng; Silvia Chiang; Margaret R Spitz
Journal:  Cancer Res       Date:  2005-01-01       Impact factor: 12.701

6.  Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer.

Authors:  H Kawasaki; D C Altieri; C D Lu; M Toyoda; T Tenjo; N Tanigawa
Journal:  Cancer Res       Date:  1998-11-15       Impact factor: 12.701

Review 7.  p53 mutations in human cancers.

Authors:  M Hollstein; D Sidransky; B Vogelstein; C C Harris
Journal:  Science       Date:  1991-07-05       Impact factor: 47.728

8.  Multiple Ras functions can contribute to mammalian cell transformation.

Authors:  M A White; C Nicolette; A Minden; A Polverino; L Van Aelst; M Karin; M H Wigler
Journal:  Cell       Date:  1995-02-24       Impact factor: 41.582

9.  High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients.

Authors:  G-B Qiao; Y-L Wu; X-N Yang; W-Z Zhong; D Xie; X-Y Guan; D Fischer; H-C Kolberg; S Kruger; H-W Stuerzbecher
Journal:  Br J Cancer       Date:  2005-07-11       Impact factor: 7.640

10.  Effects of simian virus 40 large and small tumor antigens on mammalian target of rapamycin signaling: small tumor antigen mediates hypophosphorylation of eIF4E-binding protein 1 late in infection.

Authors:  Yongjun Yu; Sagar B Kudchodkar; James C Alwine
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

View more
  10 in total

1.  The VEGF receptor neuropilin 2 promotes homologous recombination by stimulating YAP/TAZ-mediated Rad51 expression.

Authors:  Ameer L Elaimy; John J Amante; Lihua Julie Zhu; Mengdie Wang; Charlotte S Walmsley; Thomas J FitzGerald; Hira Lal Goel; Arthur M Mercurio
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-24       Impact factor: 11.205

2.  A peptide nucleic acid targeting nuclear RAD51 sensitizes multiple myeloma cells to melphalan treatment.

Authors:  David Abasiwani Alagpulinsa; Shmuel Yaccoby; Srinivas Ayyadevara; Robert Joseph Shmookler Reis
Journal:  Cancer Biol Ther       Date:  2015-05-21       Impact factor: 4.742

3.  BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells.

Authors:  Grazia Ambrosini; Ashley D Sawle; Elgilda Musi; Gary K Schwartz
Journal:  Oncotarget       Date:  2015-10-20

4.  Melanoma cells replicate through chemotherapy by reducing levels of key homologous recombination protein RAD51 and increasing expression of translesion synthesis DNA polymerase ζ.

Authors:  Liang Song; Ewan M McNeil; Ann-Marie Ritchie; Katy R Astell; Charlie Gourley; David W Melton
Journal:  BMC Cancer       Date:  2017-12-18       Impact factor: 4.430

5.  Targeting Rad51 as a strategy for the treatment of melanoma cells resistant to MAPK pathway inhibition.

Authors:  Elena Makino; Lisa Marie Fröhlich; Tobias Sinnberg; Corinna Kosnopfel; Birgit Sauer; Claus Garbe; Birgit Schittek
Journal:  Cell Death Dis       Date:  2020-07-02       Impact factor: 8.469

6.  Elp1 facilitates RAD51-mediated homologous recombination repair via translational regulation.

Authors:  Wei-Ting Chen; Huan-Yi Tseng; Chung-Lin Jiang; Chih-Ying Lee; Peter Chi; Liuh-Yow Chen; Kai-Yin Lo; I-Ching Wang; Fu-Jung Lin
Journal:  J Biomed Sci       Date:  2021-11-24       Impact factor: 8.410

Review 7.  p53 in the DNA-Damage-Repair Process.

Authors:  Ashley B Williams; Björn Schumacher
Journal:  Cold Spring Harb Perspect Med       Date:  2016-05-02       Impact factor: 6.915

Review 8.  How the Other Half Lives: What p53 Does When It Is Not Being a Transcription Factor.

Authors:  Teresa Ho; Ban Xiong Tan; David Lane
Journal:  Int J Mol Sci       Date:  2019-12-18       Impact factor: 5.923

Review 9.  Do Mutations Turn p53 into an Oncogene?

Authors:  Consuelo Pitolli; Ying Wang; Mara Mancini; Yufang Shi; Gerry Melino; Ivano Amelio
Journal:  Int J Mol Sci       Date:  2019-12-11       Impact factor: 5.923

10.  Regulation and pharmacological targeting of RAD51 in cancer.

Authors:  McKenzie K Grundy; Ronald J Buckanovich; Kara A Bernstein
Journal:  NAR Cancer       Date:  2020-09-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.